Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Pfizer
Hoffmann-La Roche
Boehringer Ingelheim
Takeda
Bolt Biotherapeutics, Inc.
Shasqi, Inc.
Tempus AI
Actym Therapeutics, Inc.
Bolt Biotherapeutics, Inc.
Elevation Oncology
Aminex Therapeutics, Inc.
Inhibrx Biosciences, Inc
Novartis
Merck Sharp & Dohme LLC
Pfizer
Ikena Oncology
Washington University School of Medicine
Yale University
CytomX Therapeutics
Fate Therapeutics
Fate Therapeutics
Hoffmann-La Roche
Seagen Inc.
Repertoire Immune Medicines
Montefiore Medical Center
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Tocagen Inc.
University of Wisconsin, Madison
University of Arizona
CureOne
Institut Cancerologie de l'Ouest
University of Pittsburgh
Celldex Therapeutics
Loma Linda University
Masonic Cancer Center, University of Minnesota
Merck Sharp & Dohme LLC
Papworth Hospital NHS Foundation Trust
Stanford University
Dana-Farber Cancer Institute
Yale University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
University of Wisconsin, Madison